- Home
- GOVX vs BIVI Comparison
GOVX vs BIVI Comparison
Compare GOVX & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- BIVI
- Stock Information
- Founded
- GOVX 2001
- BIVI 2013
- Country
- GOVX United States
- BIVI United States
- Employees
- GOVX N/A
- BIVI N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- GOVX Health Care
- BIVI Health Care
- Exchange
- GOVX Nasdaq
- BIVI Nasdaq
- Market Cap
- GOVX 16.8M
- BIVI 14.2M
- IPO Year
- GOVX N/A
- BIVI N/A
- Fundamental
- Price
- GOVX $0.41
- BIVI $1.43
- Analyst Decision
- GOVX Strong Buy
- BIVI
- Analyst Count
- GOVX 2
- BIVI 0
- Target Price
- GOVX $7.00
- BIVI N/A
- AVG Volume (30 Days)
- GOVX 524.6K
- BIVI 93.3K
- Earning Date
- GOVX 11-13-2025
- BIVI 11-10-2025
- Dividend Yield
- GOVX N/A
- BIVI N/A
- EPS Growth
- GOVX N/A
- BIVI N/A
- EPS
- GOVX N/A
- BIVI N/A
- Revenue
- GOVX $3,353,560.00
- BIVI N/A
- Revenue This Year
- GOVX N/A
- BIVI N/A
- Revenue Next Year
- GOVX N/A
- BIVI N/A
- P/E Ratio
- GOVX N/A
- BIVI N/A
- Revenue Growth
- GOVX 8.52
- BIVI N/A
- 52 Week Low
- GOVX $0.37
- BIVI $1.25
- 52 Week High
- GOVX $3.01
- BIVI $31.50
- Technical
- Relative Strength Index (RSI)
- GOVX 35.66
- BIVI 42.63
- Support Level
- GOVX $0.37
- BIVI $1.25
- Resistance Level
- GOVX $0.44
- BIVI $1.41
- Average True Range (ATR)
- GOVX 0.03
- BIVI 0.11
- MACD
- GOVX -0.00
- BIVI 0.00
- Stochastic Oscillator
- GOVX 26.59
- BIVI 48.82
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.